A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
- Status
- WITHDRAWN
- Phase
- PHASE2
Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
- Status
- COMPLETED
- Phase
- PHASE2
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Status
- COMPLETED
- Phase
- PHASE3
Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance
- Status
- UNKNOWN
- Phase
- PHASE2
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE2
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
- Status
- COMPLETED
- Phase
- PHASE3
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
- Status
- UNKNOWN
- Phase
- PHASE2